Ahmet GÖKÇE, Fatih Rüştü YALÇINKAYA, Mürsel DAVARCI, Mevlana Derya BALBAY

The relationship between serum lipid levels and benign prostatic hyperplasia

Yaşlı erkeklerde benign prostat hiperplazisi (BPH) prostatın malign olmayan hastalıkları içinde en yaygın olanı olmasına rağmen etiyolojisi ve patofizyolojisi henüz tam olarak anlaşılabilmiş değildir. Bu nedenle biz de BPH hastalarındaki serum lipid değerleri ile prostat boyutları arasındaki ilişkiyi araştırdık. Semptomatik benign prostat hiperplazisi olan 37 hasta ile yaşça farklı olmayan ve herhangi bir alt üriner sistem şikayeti olmayan 43 sağlıklı olgu bu çalışmaya dahil edildi. Çalışmaya alınan bütün olgular fizik muayene, uluslararası prostat semptom skoru (IPSS), serum lipid değerleri, prostat spesifik antijen (PSA) ve abdominal ultrasonografi ile değerlendirildi. Çalışmaya alınan BPH hastalarının ve sağlıklı kontrol grubunun prostat büyüklükleri sırasıyla 53,5±12,6 g ve 45,6±12,1 g idi. Hasta grubu (205,7±31,9) ile kontrol grubunun (189,2±35,3) ortalama total kolesterol konsantrasyonları karşılaştırıldığında aralarında istatistiksel olarak anlamlı fark olduğu gözlendi (p=0,03). Hastaların ortalama PSA değerleri 2,3±2,02 idi ve kontrol grubunun PSA değeri olan 1,1±1,0 değerinden farklı bulundu (p=0,002). Sonuç olarak kontrol grubu ile karşılaştırdığımızda prostat boyutları, PSA ve total kolesterol konsantrasyonunu BPH hastalarında daha yüksek bulduk.

Serum lipid değerleri ile benign prostat hiperplazisi arasındaki ilişki

Although benign prostatic hyperplasia (BPH) is the most common non-malignant condition of the prostate in aging men, little is known about its aetiology and pathophysiology. Thus, we evaluated serum lipid profile in BPH cases and their association with prostate size. Thirty-seven consecutive symptomatic cases of BPH and fourty-three age-matched healthy controls who did not have any lower urinary tract symptoms were included in this study. All the participants had undergone a urological investigation which included International Prostate Symptom Score (IPSS), prostate specific antigen (PSA) and prostate volume measured with transabdominal ultrasonography. Serum lipid concentrations of the subjects were also determined. The mean prostate size of patients in the study group was 53.5±12.6 g and 45.6±12.1 g for subjects in control group (p=0.005). The comparison of the mean total cholesterol concentration between the study (205.7± 31.9) and the control groups (189.2±35.3) revealed a significant difference (p=0.03). The mean PSA of patients was 2.3±2.02 and 1.1±1.0 for subjects in control group (p=0.002). We found that prostate size, PSA, and total cholesterol concentrations were significantly higher in BPH cases compared to controls.

PDF

___

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-9.
2. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91: 2562-8.
3. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006;68: 1198-205.
4. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005;96: 88-92.
5. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140: 989-1002.
6. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007;177: 1395-400.
7. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005;29: 310-6.
8. Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C. Serum lipid levels in benign prostatic hyperplasia. World J Urol 2006;24: 210-3.
9. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, Shin Y, et al. A highrisk group for prostatism: a population-based epidemiological study in Korea. Br J Urol 1997;79: 736-41.
10. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8: 29-36.
11. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39: 151-8.
12. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006;370: 89-93.
13. Krotkiewski M. Role of muscle capillarization and morphology in the development of insulin resistance and metabolic syndrome. Presse Med 1994;23: 1353-6.
14. Hammarsten J, Hogstedt B, Holthuis N and Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1: 157-62.
15. Geller J. Overview of benign prostatic hypertrophy. Urology 1989;34: 57-63; discussion 87-96.
16. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145: 405-9.
17. Zumoff B. Relationship of obesity to blood estrogens. Cancer Res 1982;42: 3289-94.